ATYR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATYR To Contact Him Directly To Discuss Their Options

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ATyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][3]. Group 1: Legal Investigation - The firm is reminding investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against ATyr Pharma [2]. - The complaint alleges that ATyr and its executives violated federal securities laws by making false statements and failing to disclose material adverse facts about Efzofitimod [3]. Group 2: Drug Efficacy and Market Impact - In the EFZO-FIT study, Efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod versus 40.2% on placebo [4]. - Following the release of these results, ATyr's stock plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [4].